Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010088729 - COMPOSITIONS AND USES THEREFOR

Publication Number WO/2010/088729
Publication Date 12.08.2010
International Application No. PCT/AU2010/000113
International Filing Date 04.02.2010
IPC
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/435 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Applicants
  • UNIVERSITY OF TASMANIA THROUGH THE MENZIES RESEARCH INSTITUTE [AU]/[AU] (AllExceptUS)
  • MONASH UNIVERSITY [AU]/[AU] (AllExceptUS)
  • KERR, Megan [AU]/[AU]
  • SMALL, David [AU]/[AU] (UsOnly)
  • LAWEN, Alfons [AU]/[AU] (UsOnly)
Inventors
  • KERR, Megan
  • SMALL, David
  • LAWEN, Alfons
Agents
  • HUTCHISON, Jane
Priority Data
200990040804.02.2009AU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND USES THEREFOR
(FR) COMPOSITIONS ET LEURS UTILISATIONS
Abstract
(EN)
The invention is directed inter alia to the use of receptor-associated protein (RAP) polypeptide or a functional analog thereof to reduce amyloid oligomerisation and deposition and to reduce Aβ associated neuropathologic features. Thus, the invention provides a composition comprising RAP or an analog thereof which binds β-amyloid peptide (Aβ) for use in the treatment or prophylaxis of a symptom of Alzheimer's disease (AD) or a related condition in a subject. One illustrative symptom is memory loss or consolidation. In another aspect, the invention provides methods of screening for RAP polypeptide functional variants or analogs by testing the ability of an agent to compete successfully with RAP for binding to Aβ.
(FR)
L'invention porte entre autres sur l'utilisation d'un polypeptide de protéine associé à un récepteur (RAP) ou d'un analogue fonctionnel de celui-ci dans le but de réduire l'oligomérisation et le dépôt d'amyloïde et de réduire les caractéristiques neuropathologiques associées à Aβ. Ainsi, l'invention fournit une composition comprenant un RAP ou un analogue de celui-ci qui se lie au peptide β-amyloïde (Aβ) pour utilisation dans le traitement ou la prophylaxie d'un symptôme de la maladie d'Alzheimer (AD) ou d'un état apparenté chez un sujet. Un symptôme illustratif est la perte ou la consolidation de la mémoire. Sous un autre aspect, l'invention porte sur des procédés de criblage pour des variantes fonctionnelles du polypeptide RAP ou analogues par le test de la capacité d'un agent à entrer en compétition avec succès avec le RAP pour se lier à Aβ.
Also published as
Latest bibliographic data on file with the International Bureau